Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Stockholm - Delayed Quote SEK

Biosergen AB (BIOSGN.ST)

0.2950
-0.0020
(-0.67%)
At close: April 25 at 4:39:51 PM GMT+2
Currency in SEK All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Cost of Revenue
--
--
456
280
178
Gross Profit
--
--
-456
-280
-178
Operating Expense
18,589
18,589
26,810
34,524
33,900
Operating Income
-18,589
-18,589
-27,266
-34,804
-34,078
Net Non Operating Interest Income Expense
-202
-202
229
81
-240
Pretax Income
-18,791
-18,791
-27,037
-34,048
-34,318
Net Income Common Stockholders
-18,791
-18,791
-27,037
-34,048
-34,318
Diluted NI Available to Com Stockholders
-18,791
-18,791
-27,037
-34,048
-34,318
Basic EPS
-0.15
--
-0.53
-0.64
-0.72
Diluted EPS
-0.15
--
-0.53
-0.64
-0.72
Basic Average Shares
163,718.5800
--
85,727.9410
52,832.4390
47,577.0690
Diluted Average Shares
163,718.5800
--
85,727.9410
52,832.4390
47,577.0690
Total Operating Income as Reported
-18,589
-18,589
-27,266
-34,129
-34,078
Total Expenses
18,589
18,589
27,266
34,804
34,078
Net Income from Continuing & Discontinued Operation
-18,791
-18,791
-27,037
-34,048
-34,318
Normalized Income
-18,791
-18,791
-27,037
-34,048
-34,318
Interest Income
--
--
237
135
--
Interest Expense
--
--
9
54
240
Net Interest Income
-202
-202
229
81
-240
EBIT
-18,589
-18,589
-27,266
-33,994
-34,078
EBITDA
-18,589
-18,589
-27,266
-33,994
-34,078
Reconciled Cost of Revenue
--
--
456
280
178
Net Income from Continuing Operation Net Minority Interest
-18,791
-18,791
-27,037
-34,048
-34,318
Normalized EBITDA
-18,589
-18,589
-27,266
-33,994
-34,078
12/31/2021 - 6/24/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ZLDPF Zealand Pharma A/S
65.16
+1.02%
 
BVNRY Bavarian Nordic A/S
7.73
+0.52%
 
ALK-B.CO ALK-Abelló A/S
146.80
+0.07%
 
GUBRA.CO Gubra A/S
354.00
-2.53%
 
ASND Ascendis Pharma A/S
164.15
+2.31%
 
IRD Opus Genetics, Inc.
0.8402
+5.02%
 
GMAB Genmab A/S
20.59
+0.24%
 
OTLK Outlook Therapeutics, Inc.
1.5300
-1.29%
 
ZEAL.CO Zealand Pharma A/S
420.50
-1.06%
 
GMAB.CO Genmab A/S
1,347.00
+0.52%